Rein Therapeutics (RNTX) Q4 2025 earnings summary

Executive summary

• Focused on developing therapies for orphan pulmonary and fibrosis indications, with LTI-03 as the lead candidate in Phase 2 trials for idiopathic pulmonary fibrosis (IPF).

• LTI-01 and preclinical programs paused indefinitely due to capital constraints; resources are allocated to LTI-03.

• No product revenue to date; operations funded by equity, warrants, and debt financings.

• Net losses continue, with substantial doubt about ability to continue as a going concern without additional funding.

Financial highlights

• Net loss for 2025 was $49.9 million, compared to $62.9 million in 2024.

• Research and development expenses decreased to $11.0 million in 2025 from $14.2 million in 2024.

• General and administrative expenses were $10.9 million in 2025, down from $13.9 million in 2024.

• Impairment loss on intangible assets was $28.7 million in 2025, reflecting the indefinite pause of LTI-01 and preclinical programs.

• Cash and cash equivalents at year-end 2025 were $3.2 million.

Outlook and guidance

• Existing cash and recent financing expected to fund operations into Q2 2026, but not sufficient to complete the Phase 2 RENEW trial.

• Additional capital is required to sustain operations and complete clinical development.

• Initial interim topline data from the RENEW Phase 2 trial expected in Q4 2026.